[go: up one dir, main page]

WO2008090944A1 - スピロ環化合物 - Google Patents

スピロ環化合物 Download PDF

Info

Publication number
WO2008090944A1
WO2008090944A1 PCT/JP2008/050949 JP2008050949W WO2008090944A1 WO 2008090944 A1 WO2008090944 A1 WO 2008090944A1 JP 2008050949 W JP2008050949 W JP 2008050949W WO 2008090944 A1 WO2008090944 A1 WO 2008090944A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
membered
aromatic heterocyclic
spiro
nitrogenated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/050949
Other languages
English (en)
French (fr)
Inventor
Kohji Fukatsu
Makoto Kamata
Tohru Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to US12/449,084 priority Critical patent/US20100093777A1/en
Priority to EP08703778A priority patent/EP2128163A1/en
Priority to JP2008555099A priority patent/JPWO2008090944A1/ja
Publication of WO2008090944A1 publication Critical patent/WO2008090944A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)

Abstract

本発明は、アセチル－ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害作用を有し、肥満症、糖尿病、高血圧症、高脂血症、心不全、糖尿病性合併症、メタボリックシンドローム、筋肉減少症、または癌等の予防・治療に有用であり、かつ優れた薬効を有する式（Ｉ）で表される化合物またはその塩を提供するものである。 ［式中、Ｒ１は、水素原子または置換基を；環Ｐは、置換されていてもよい６員の含窒素芳香族複素環を；環Ｑは、さらに置換されていてもよい５ないし７員の含窒素非芳香族複素環を； 環Ｒは、さらに置換されていてもよく、縮合していてもよい５ないし７員の芳香環を示す。］
PCT/JP2008/050949 2007-01-25 2008-01-24 スピロ環化合物 Ceased WO2008090944A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/449,084 US20100093777A1 (en) 2007-01-25 2008-01-24 Spiro-ring compound
EP08703778A EP2128163A1 (en) 2007-01-25 2008-01-24 Spiro-ring compound
JP2008555099A JPWO2008090944A1 (ja) 2007-01-25 2008-01-24 スピロ環化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007015593 2007-01-25
JP2007-015593 2007-01-25

Publications (1)

Publication Number Publication Date
WO2008090944A1 true WO2008090944A1 (ja) 2008-07-31

Family

ID=39644518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050949 Ceased WO2008090944A1 (ja) 2007-01-25 2008-01-24 スピロ環化合物

Country Status (4)

Country Link
US (1) US20100093777A1 (ja)
EP (1) EP2128163A1 (ja)
JP (1) JPWO2008090944A1 (ja)
WO (1) WO2008090944A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2398320A4 (en) * 2009-02-19 2012-09-19 Univ Vanderbilt ALLOSTERIC ANTAGONISTS OF AMIDOBIPIPERIDINECARBOXYLATE M1, ANALOGUES AND DERIVATIVES THEREOF, AND METHODS FOR THEIR MANUFACTURE AND USE
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2013525262A (ja) * 2010-04-27 2013-06-20 武田薬品工業株式会社 二環性化合物
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
WO2003029245A1 (en) 2001-10-01 2003-04-10 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
JP2003533509A (ja) * 2000-05-19 2003-11-11 メルク シャープ エンド ドーム リミテッド シクロヘキサン誘導体および治療薬としてのその使用
WO2004000846A1 (en) 2002-06-20 2003-12-31 Celltech R & D Limited Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
WO2004026873A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤
JP2005119987A (ja) * 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005075484A2 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
WO2005097795A1 (en) * 2004-04-06 2005-10-20 Janssen Pharmaceutica N.V. Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
WO2006053024A2 (en) 2004-11-10 2006-05-18 Incyte Corporation Lactam compounds and their use as pharmaceuticals
JP2006131559A (ja) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
JP2007015593A (ja) 2005-07-08 2007-01-25 Advics:Kk 車体速度演算装置
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
WO2007119833A1 (ja) * 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited 含窒素複素環化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3522638A1 (de) * 1985-06-25 1987-01-08 Diamalt Ag Neue somatostatin-derivate

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
WO2001014372A2 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
WO2001087834A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2003533509A (ja) * 2000-05-19 2003-11-11 メルク シャープ エンド ドーム リミテッド シクロヘキサン誘導体および治療薬としてのその使用
JP2005510476A (ja) * 2001-10-01 2005-04-21 ブリストル−マイヤーズ　スクイブ　カンパニー 抗炎症剤として有用なスピロ−ヒダントイン化合物
WO2003029245A1 (en) 2001-10-01 2003-04-10 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
US20030187254A1 (en) * 2002-02-27 2003-10-02 Pfizer Inc. Acetyl-CoA carboxylase inhibitors
WO2004000846A1 (en) 2002-06-20 2003-12-31 Celltech R & D Limited Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors
WO2004026873A1 (ja) * 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤
JP2005119987A (ja) * 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005075484A2 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
WO2005097795A1 (en) * 2004-04-06 2005-10-20 Janssen Pharmaceutica N.V. Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
JP2006131559A (ja) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
WO2006053024A2 (en) 2004-11-10 2006-05-18 Incyte Corporation Lactam compounds and their use as pharmaceuticals
JP2007015593A (ja) 2005-07-08 2007-01-25 Advics:Kk 車体速度演算装置
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
WO2007119833A1 (ja) * 2006-04-14 2007-10-25 Takeda Pharmaceutical Company Limited 含窒素複素環化合物

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations", 1989, VCH PUBLISHERS INC.
"Jikken Kagaku Kouza", vol. 20, pages: 304
"ORGANIC FUNCTIONAL GROUP PREPARATIONS", 1989, ACADEMIC PRESS, INC.
"Protective Groups in Organic Synthesis", 1980, JOHN WILEY AND SONS
ADA, 1997
BIOORGANIC AND MEDICINAL CHEMISTRY, 1999, pages 2945 - 2952
HELVETICA CHIMICA ACTA, 1983, pages 450 - 465
HETEROCYCLES, 1992, pages 2263 - 2267
IYAKUHIN NO KAIHATSU: "Design of Molecules", vol. 7, 1990, HIROKAWA SHOTEN, article "Development of Pharmaceuticals", pages: 163 - 198
JOURNAL OF MEDICINAL CHEMISTRY, 1988, pages 486 - 491
JOURNAL OF MEDICINAL CHEMISTRY, 1990, pages 820 - 826
JOURNAL OF MEDICINAL CHEMISTRY, 1998, pages 2439 - 2441
JOURNAL OF MEDICINAL CHEMISTRY, 1998, pages 4118 - 4129
JOURNAL OF MEDICINAL CHEMISTRY, 2004, pages 2441 - 2450
JOURNAL OF ORGANIC CHEMISTRY, 2004, pages 2441 - 2450
TETRAHEDRON LETTERS, 1986, pages 3285 - 3288
TETRAHEDRON LETTERS, 2001, pages 8345 - 8349

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050445A1 (ja) 2008-10-27 2010-05-06 武田薬品工業株式会社 二環性化合物
EP2398320A4 (en) * 2009-02-19 2012-09-19 Univ Vanderbilt ALLOSTERIC ANTAGONISTS OF AMIDOBIPIPERIDINECARBOXYLATE M1, ANALOGUES AND DERIVATIVES THEREOF, AND METHODS FOR THEIR MANUFACTURE AND USE
JP2013525262A (ja) * 2010-04-27 2013-06-20 武田薬品工業株式会社 二環性化合物
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2015036892A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2023090411A1 (ja) 2021-11-19 2023-05-25 塩野義製薬株式会社 心疾患または骨格筋の疾患の治療用医薬

Also Published As

Publication number Publication date
JPWO2008090944A1 (ja) 2010-05-20
EP2128163A1 (en) 2009-12-02
US20100093777A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2008090944A1 (ja) スピロ環化合物
WO2008102749A1 (ja) 複素環化合物
WO2006112549A8 (ja) 縮合複素環化合物
TN2011000362A1 (en) Pyridazinone compounds
UA94424C2 (en) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
GB0428514D0 (en) Compounds
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
WO2009041447A1 (ja) ５員複素環化合物
WO2008001931A3 (en) Fused cyclic compounds
MY163114A (en) Cyclopentylacrylamide derivative
EA200500322A1 (ru) Соединения дигидропиразолопиридина
MY158982A (en) Heterocyclic compound
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
WO2009057784A1 (ja) 複素環化合物
WO2009100872A8 (en) Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EA201170735A1 (ru) Производные бензотиазола в качестве средств против рака
WO2005097129A3 (en) 6-azaindole compound
WO2007118185A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
EP1845081A4 (en) amide
WO2009025358A1 (ja) 複素環化合物およびその用途
WO2008120655A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有するオキサゾリジノン誘導体
EP1813606A4 (en) amide
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2008093677A1 (ja) 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
WO2008142859A1 (ja) 新規なスピロオキシインドール化合物及びこれを含有する医薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703778

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008555099

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12449084

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008703778

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE